AQUIOS CL Flow Cytometer Accepted by WHO Prequalification of In Vitro Diagnostics Programme
Fast, Compact, Fully Automated Instrument for CD4 Monitoring
The AQUIOS CL flow cytometer has been accepted by the World Health Organization (WHO) Prequalification of In Vitro Diagnostics Program. It can be used specifically for the immunologic assessment of patients having, or suspected of having, immune deficiency.
The World Health Organization (WHO) Prequalification of In Vitro Diagnostics (IVDs) Programme aims to promote and facilitate access to safe, appropriate and affordable in vitro diagnostics of good quality in an equitable manner. Focus is placed on in vitro diagnostics for priority diseases and their suitability for use in resource-limited settings.
The Prequalification IVD Programme has accepted the AQUIOS CL cytometer together with the AQUIOS Tetra‐1 Panel (CD45‐FITC/CD4‐RD1/CD8‐ ECD/CD3‐PC5) and AQUIOS Immuno‐Trol/Immuno‐Trol low controls. They are intended for use with in‐vitro diagnostic flow cytometric applications, involving four fluorescent detection channels using a blue (488 nm) laser, two light scatter detection channels and electronic volume (EV).**
“Beckman Coulter is committed to developing HIV monitoring solutions that contribute directly to the treatment process”, explained Mario Koksch PhD, Vice President of the Cytometry Unit for Beckman Coulter Life Sciences.
The company’s CARES Global Health Initiative is designed to provide innovative solutions for the monitoring of HIV and AIDS treatment. It started in 2004 after Professor Debbie Glencross, a South African laboratory pathologist, found a different and less expensive way to measure a patient’s CD4 count. The development of this compact, fully automated instrument to run that assay and carry out the accurate characterization of T cell CD4 subsets is the latest part of this initiative.
The AQUIOS is the first authentic ‘LOAD & GO’ cytometry system and designed specifically to streamline workflow and reduce backlogs when handling applications, such as immunophenotyping. It is suitable for clinical labs of all sizes and requires minimal training to operate.
Explaining the benefits of the compact instrument for use in resource-limited labs, Dr Koksch added:
“The small footprint, high-throughput AQUIOS helps improve workflow in all sizes of labs, even those with limited access to highly trained staff. In addition, its cap piercing technology provides additional safety for staff reducing their need to handle open blood tubes and risk exposure to biohazardous material.”
Fill the form to download Workflow Comparison Study with AQUIOS CL Flow Cytometer
Innovation In CD4 Testing
HIV Advanced Disease Management More than a third of people starting ART have advanced HIV disease, and an increasing number of patients develop an advanced HIV after disengaging from care.
HIV Diagnosis Becomes up to Four Times Faster Thanks to This InventionHIV/AIDS Africa’s most vulnerable can benefit from simple test which monitors disease progression, enabling the comprehensive treatment programs.
AQUIOS CL Flow Cytometer Accepted by WHO Prequalification of In Vitro Diagnostics ProgrammeThe AQUIOS CL flow cytometer has been accepted by the World Health Organization (WHO) Prequalification of In Vitro Diagnostics Program.
Case Study: London Health Sciences Centre (LHSC)AQUIOS CL provides faster times to first result, faster turnaround times and faster total elapsed times, with fewer total steps and less hands-on time.
**These reagents provide identification and enumeration of the following lymphocyte subset populations:
- total CD3+, CD3+CD4+,CD3+CD8+, CD3+CD4+/CD3+CD8+ (ratio only) lymphocyte percentages and absolute counts;
- CD45+ absolute count; and
- CD45+ Low SS (lymphocytes) percentage and absolute count.